Antengene Corporation Limited (06996.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 16Sep 21Sep 24Sep 29Oct 5Oct 8Oct 13Oct 16

Key dataOct 16, 2026

OpenHKD 3.10

From 52W high−50.16%

Volume705500.00

Market capHKD 1.93B

P/E (TTM)32.8x

P/S (TTM)2.9x

Div yield—

Key dataOct 16, 2026

Open

HKD 3.10

From 52W high

−50.16%

Volume

705500.00

Market cap

HKD 1.93B

ValuationView details →

P/E (Fwd)

13.6x

EV/EBITDA

6.6x

P/E (TTM)

32.8x

RSI (14)

38.6

MomentumView details →

1D Return

+3.70%

YTD Return

−18.73%

ValuationView details →

P/E (Fwd)

13.6x

P/E (TTM)

32.8x

EV/EBITDA

6.6x

EV/Sales

2.0x

P/S (TTM)

2.9x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

91.47%

Net Margin

9.07%

EBITDA Margin

31.01%

ROE (TTM)

5.55%

ROA (TTM)

3.33%

Asset Turnover

0.40x

GrowthView details →

Revenue YoY

+561.68%

EPS YoY

+122.22%

FCF YoY

+55.53%

Revenue CAGR 3Y

−13.03%

EPS CAGR 3Y

+25.49%

EBITDA YoY

+166.20%

MomentumView details →

1D Return

+3.70%

YTD Return

−18.73%

1Y Return

−36.76%

RSI (14)

38.6

vs 50D SMA

−15.02%

vs 200D SMA

−23.54%

Capital & dividendView details →

Debt/Equity

0.28x

Current Ratio

4.95x

Quick Ratio

4.91x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.39

EPS Surprise

−8.10%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.23

Avg Surprise (4Q)

−8.10%

Rev Surprise

14.68%

Financials snapshotView financials →

Revenue (TTM)

642.50M

Net Income (TTM)

−177.99M

Op. CF (TTM)

−312.11M

Next earningsMar 19, 2027 →

Latest newsMore news →

Antengene announced that its Phase I ATTRACT study of ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B-cell related autoimmune diseases, received approval from the Australian Human Research Ethics Committee and completed the Clinical Trial Notification submission to the Therapeutic Goods Administration.53d ago

Antengene Corporation reported interim results for the six months ended June 30, 2026, with revenue of RMB 513 million, up 865% year-over-year, and a net profit of RMB 216 million, reversing a loss of RMB 76.378 million in the prior-year period.56d ago

Similar companies

AIM Vaccine Co., Ltd.06660.HK Clover Biopharmaceuticals, Ltd.02197.HK Immunome, Inc.IMNM Pharvaris N.V.PHVS *ST海利603718.SH Galapagos N.V. Sponsored ADRLKFT Find similar companies →

Latest newsMore news →

Antengene announced that its Phase I ATTRACT study of ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B-cell related autoimmune diseases, received approval from the Australian Human Research Ethics Committee and completed the Clinical Trial Notification submission to the Therapeutic Goods Administration.53d ago Antengene Corporation reported interim results for the six months ended June 30, 2026, with revenue of RMB 513 million, up 865% year-over-year, and a net profit of RMB 216 million, reversing a loss of RMB 76.378 million in the prior-year period.56d ago